Resverlogix: The Future of Drug Development

October 4, 2021

Developing safe, epigenetic therapeutics for people suffering from chronic illnesses

Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.

The Company was founded in 2001 by Donald McCaffrey and Norman Wong. They're a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. They provide novel science, clinical, and value-based health solutions to key stakeholders such as pharmaceutical, physician, and health payer groups.

For more information on Resverlogix Corp. (TSX: RVX) please click the investor request info button.

You might also like

Healthcare
Brompton Funds: Global Healthcare Income & Growth ETF

Global Healthcare Management is active management and distributions program. It will gain knowledge of the established and emerging concept.

Healthcare
CEO Clips - Unicycive Therapeutics: Innovation to Improve Quality of Life For Patients Suffering from Kidney Diseases

Developing life-changing new medicines to treat a variety of kidney diseases with significant unmet medical needs.

Content Broadcast on: BNN Bloomberg, Bloomberg, FOX Business News, BIZTV, Reuters, YouTube and more!